While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

This will be the final test of proving whether or not ANKTIVA in combination with either Keytruda or Opdivo will be able to beat SOC for these patients. According to the 10-Q SEC Filing ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

Merck & Co and its Keytruda (pembrolizumab) is following Bristol-Myers Squibb (BMS) and its rival cancer immunotherapy, Opdivo (nivolumab), into the classical Hodgkin Lymphoma (cHL) indication.

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

The company's Opdivo continues to compete with Merck & Co.'s Keytruda, with the upcoming SC formulation of Opdivo potentially helping BMY to compete more effectively. In the schizophrenia treatment ...

However, BMS’ setback is further good news for MSD’s Keytruda, which now looks increasingly likely to become the dominant player in NSCLC globally, after Opdivo failed to show efficacy as a ...